VRCA VERRICA PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, VERRICA PHARMACEUTICALS INC reported revenue of $5.86M (down 53.8% from a year earlier), net income of −$13.2M and diluted EPS of −$0.62; over the last four quarters revenue was $30.3M and net income −$31.2M; for the fiscal year ended December 2025 revenue was $35.6M, up 370.2% on the year before.
VRCA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $35.6M, gross profit n/a, operating income −$12.2M, net income −$17.9M (margin -50.3%), EPS −$1.68
- Fiscal year ended Dec 2024: revenue $7.57M, gross profit n/a, operating income −$65.9M, net income −$76.6M (margin -1012.4%), EPS −$14.78
- Fiscal year ended Dec 2023: revenue $5.12M, gross profit n/a, operating income −$65.8M, net income −$67.0M (margin -1307.6%), EPS −$1.48
- Fiscal year ended Dec 2022: revenue $9.03M, gross profit n/a, operating income −$21.3M, net income −$24.5M (margin -271.1%), EPS −$0.72
- Fiscal year ended Dec 2021: revenue $12.0M, gross profit n/a, operating income −$30.9M, net income −$35.1M (margin -292.3%), EPS −$1.30
VRCA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $5.86M (down 53.8% year over year), net income −$13.2M, EPS −$0.62
- Quarter ended Mar 31, 2026: revenue $5.02M (up 46.1% year over year), net income −$9.68M, EPS −$0.45
- Quarter ended Dec 31, 2025 (from the annual report): revenue $5.09M (up 1380.2% year over year), net income −$8.09M, EPS −$0.64
- Quarter ended Sep 30, 2025: revenue $14.3M (up 905.4% year over year), net income −$274K, EPS −$0.03
- Quarter ended Jun 30, 2025: revenue $12.7M (up 145.4% year over year), net income $204K, EPS $0.02
- Quarter ended Mar 31, 2025: revenue $3.44M (down 10.1% year over year), net income −$9.74M, EPS −$1.03
- Quarter ended Dec 31, 2024 (from the annual report): revenue $344K (down 82.7% year over year), net income −$16.2M, EPS −$5.76
- Quarter ended Sep 30, 2024: revenue −$1.78M (down 161.1% year over year), net income −$22.9M, EPS −$4.88
- Quarter ended Jun 30, 2024: revenue $5.18M (up 2744.5% year over year), net income −$17.2M, EPS −$3.70
- Quarter ended Mar 31, 2024: revenue $3.83M (up 10240.5% year over year), net income −$20.3M, EPS −$0.44
- Quarter ended Dec 31, 2023 (from the annual report): revenue $1.99M (up 2823.5% year over year), net income −$24.6M, EPS −$0.55
- Quarter ended Sep 30, 2023: revenue $2.92M (down 64.9% year over year), net income −$24.8M, EPS −$0.54
- Quarter ended Jun 30, 2023: revenue $182K (down 15.0% year over year), net income −$11.0M, EPS −$0.24
- Quarter ended Mar 31, 2023: revenue $37.0K (down 91.4% year over year), net income −$6.59M, EPS −$0.15
- Quarter ended Dec 31, 2022 (from the annual report): revenue $68.0K, net income −$5.93M, EPS −$0.04
- Quarter ended Sep 30, 2022: revenue $8.32M, net income $83.0K, EPS $0.00
- Quarter ended Jun 30, 2022: revenue $214K, net income −$10.2M, EPS −$0.37
- Quarter ended Mar 31, 2022: revenue $431K (down 96.4% year over year), net income −$8.47M, EPS −$0.31
- Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$9.54M, EPS −$0.36
- Quarter ended Sep 30, 2021: revenue $0, net income −$12.8M, EPS −$0.47
VRCA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$17.6M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$60.9M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$38.6M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$18.7M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$27.6M, share buybacks n/a
VRCA balance sheet
- Jun 30, 2026: cash $11.2M, total assets $36.0M, total liabilities $31.7M, shareholders' equity $4.31M
- Mar 31, 2026: cash $20.6M, total assets $38.8M, total liabilities $22.7M, shareholders' equity $16.1M
- Dec 31, 2025: cash $30.1M, total assets $47.1M, total liabilities $22.4M, shareholders' equity $24.7M
- Sep 30, 2025: cash $21.1M, total assets $40.9M, total liabilities $57.9M, shareholders' equity −$17.0M
- Jun 30, 2025: cash $15.4M, total assets $39.1M, total liabilities $56.6M, shareholders' equity −$17.5M
- Mar 31, 2025: cash $29.6M, total assets $42.2M, total liabilities $60.8M, shareholders' equity −$18.6M
- Dec 31, 2024: cash $46.3M, total assets $54.1M, total liabilities $64.0M, shareholders' equity −$9.86M
- Sep 30, 2024: cash $23.0M, total assets $32.9M, total liabilities $67.0M, shareholders' equity −$34.1M
What is VRCA's revenue?
VERRICA PHARMACEUTICALS INC reported $30.3M of revenue over its last four quarters, through June 30, 2026.
Is VRCA profitable?
No. VERRICA PHARMACEUTICALS INC lost $31.2M over the last four quarters.
What is VRCA's EPS?
Diluted earnings per share over the last four quarters were −$1.74; −$0.62 in the latest quarter.